Comparison of Translocator Protein Expression Between Tumefactive Multiple Sclerosis and Glioblastoma
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 658 KB, PDF document
This figure presents a comparison of molecular imaging of the translocator protein (TSPO) and contrast-enhanced MRI in 2 patients with tumefactive multiple sclerosis and glioblastoma, respectively. In the case of the tumefactive multiple sclerosis patient, TSPO uptake is primarily located centrally, while in the glioblastoma patient, TSPO uptake is predominantly situated peripherally to the central necrotic area. These findings suggest that TSPO imaging could be a noninvasive imaging technique for distinguishing between these 2 diagnoses.
Original language | English |
---|---|
Journal | Clinical Nuclear Medicine |
Volume | 48 |
Issue number | 8 |
Pages (from-to) | E403-E404 |
Number of pages | 2 |
ISSN | 0363-9762 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
- glioma, MRI, SPECT, translocator protein, tumefactive MS
Research areas
ID: 363282607